Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial autologous mesoangioblast therapy in m.3243A>G mitochondrial myopathy
2024-515129-27-00Phase 2Authorised
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous mesoangioblasts in Mitochondrial myopathies (MM) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Safety parameters and Change in muscle strength and fatigue. Planned start Nov 2024; status: authorised.
02
Drugs
autologous mesoangioblasts
03
Conditions
Mitochondrial myopathies (MM)
Beyond the preview
Go deeper on 2024-515129-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515129-27-00.